OCS

Oculis is a clinical-stage biopharmaceutical company focused on developing transformative topical treatments for ophthalmic and neuro-ophthalmic diseases. The company's lead candidate, OCS-01, is a high-concentration topical dexamethasone formulation utilizing its proprietary OPTIREACH technology, currently in Phase 3 for diabetic macular edema and post-cataract surgery inflammation. Its pipeline also includes Licaminlimab (OCS-02), a topical anti-TNF alpha antibody fragment for dry eye disease, and Privosegtor (OCS-05), a first-in-class neuroprotective agent for acute optic neuritis. Headquartered in Switzerland with operations in Iceland and the U.S., Oculis aims to replace invasive ocular injections with non-invasive topical eye drops.